Red blood cell disorders encompass a wide range of conditions affecting the production, function, or lifespan of erythrocytes. Among these, autoimmune hemolytic anemia (AIHA) presents a unique clinical challenge due to its autoimmune nature, requiring therapies that modulate the immune system. The market for treating AIHA is expanding, driven by a rising incidence of autoimmune conditions,...
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek